Last reviewed · How we verify
NCT06941948
Sleep Disorders and Tumor Immune Microenvironment
trial testing PSQI in Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer in 400 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 May 2025 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- PSQI
Conditions studied
- Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer — all drugs for Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 70, any sex, with Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Title: Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer: A Prospective Cohort Study Objective: This prospective study aims to investigate the causal relationship between sleep disorders (e.g., insomnia, obstructive sleep apnea \[OSA\]) and alterations in the tumor immune microenvironment (TIME) in lung cancer patients, and to evaluate their joint effects on immunotherapy response and long-term prognosis. Study Design: Prospective observational cohort study with 3-year follow-up. Participants: Newly diagnosed primary lung cancer patients (NSCLC/SCLC) prior to treatment initiation (n = 400, target sample size\*). Exposure Groups: Stratified by sleep disorder status (confirmed via polysomnography \[OSA\] and validated questionnaires \[e.g., PSQI ≥7 for insomnia\]).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06941948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PSQI
Trials testing the same drug.
- NCT06953765 — A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer · not yet recruiting
- NCT04549350 — Sleep Quality Among HCWs · completed
- NCT03773601 — Objective Sleep Behavior in Relation to a Nigth Competition in Athletes. · NA · completed
- NCT06953492 — Sleep State in Lung Cancer: A Retrospective Analysis · completed
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06941948 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06941948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing